Lisa Lynn Wang, MD
Department or Service
- Texas Medical Center
Director, Bone Tumors Program
Clinical Leader, Musculoskeletal Tumor Clinic
|University of North Carolina at Chapel Hill||medical school||Doctor of Medicine||1993|
|Washington University School of Medicine||bachelors||Bachelor of Arts||1988|
|Baylor College of Medicine||fellowship||Pediatric Hematology/Oncology||2001|
|Children's Hospital of Los Angeles||residency||Pediatrics||1996|
Dr. Lisa Wang is Director of the Bone Tumor Program and the Clinical Leader of the Musculoskeletal Tumor Clinic at Texas Children's Cancer Center. Dr. Wang has a special interest in sarcomas, particularly bone sarcomas such as osteosarcoma and Ewing's sarcoma.
Dr. Wang is Director of the Bone Tumor Program at Texas Children's Cancer Center. The Bone Tumor Program brings together clinical and basic science researchers who are commonly investigating various aspects of osteosarcoma biology and treatment. The Bone Tumor Program promotes advanced research and clinical activities, which center around bone sarcomas, as part of the educational initiatives for hematology-oncology fellows and students.
Dr. Lisa Wang is also the Clinical Leader of the Musculoskeletal Tumor Clinic, an interdisciplinary clinic within the outpatient clinic at Texas Children's Cancer Center. The Musculoskeletal Tumor Clinic brings together a team of clinical specialists to decide on management plans for patients with bone tumors. The team includes an orthopedic surgeon, a pediatric oncologist, a pediatric nurse practitioner, a solid tumor fellow, and a social worker, among other caregivers.
She is certified by the American Board of Pediatrics in general pediatrics and pediatric hematology/oncology.
|American Association for Cancer Research (AACR)||Member|
|American Society of Clinical Oncology (ASCO)||Member|
|American Society of Human Genetics||Member|
|American Society of Pediatric Hematology/Oncology (ASPHO)||Member|
|Children's Oncology Group (COG)||Member|
Dr. Lisa Wang’s research interests focus on the molecular pathogenesis of osteosarcoma. She specifically focuses on the RECQL4 pathway and Rothmund-Thomson syndrome (RTS), a rare, inherited disorder that predisposes affected individuals to developing osteosarcoma.
Her research goals include:
understanding the molecular basis of Rothmund-Thomdon syndrome and related disorders by studying the mechanisms that predispose individuals to cancer development;
defining the clinical phenotype and appropriate medical management of these patients; and
understanding the role of RECQL4 pathways in the pathogenesis of osteosarcoma and skeletal development.